The estimated Net Worth of Robert E Davis is at least $5.53 Million dollars as of 4 January 2019. Mr. Davis owns over 9,564 units of Intra-Cellular Therapies Inc stock worth over $3,286,858 and over the last 20 years he sold ITCI stock worth over $109,603. In addition, he makes $2,128,540 as Senior Vice President and Chief Scientific Officer at Intra-Cellular Therapies Inc.
Sign up
Mr. Davis ITCI stock SEC Form 4 insiders trading
Robert has made over 1 trades of the Intra-Cellular Therapies Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 9,564 units of ITCI stock worth $109,603 on 4 January 2019.
The largest trade he's ever made was selling 9,564 units of Intra-Cellular Therapies Inc stock on 4 January 2019 worth over $109,603. On average, Robert trades about 1,196 units every 0 days since 2005. As of 4 January 2019 he still owns at least 43,989 units of Intra-Cellular Therapies Inc stock.
You can see the complete history of Mr. Davis stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Davis biography
Robert E. Davis Ph.D., serves as Senior Vice President and Chief Scientific Officer of the Company. Previously, Dr. Davis served as President and CEO of 3-D Pharmaceutical Consultants, providing consulting services to the Company from December 2005 to November 2015. From December 2000 until November 2005, Dr. Davis served as the Executive Vice President, Research and Development at ACADIA Pharmaceuticals. From January 1994 until October 2000, Dr. Davis held various positions at MitoKor, a development stage biotechnology company focused on the design and development of drug therapies for mitochondrial diseases, serving at various times as its President, Chief Executive Officer, and Chief Scientific Officer. Earlier, Dr. Davis held various positions at Parke-Davis Pharmaceutical Research, Warner-Lambert. Earlier in his career, he participated in the discovery and development of tacrine hydrochloride, the first drug approved for treating Alzheimer’s disease; gabapentin, the first drug approved for treating neuropathic pain; and pimavanserin, the first drug approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Dr. Davis received his B.S., M.S., and Ph.D. in Psychobiology from the University of Illinois.
What is the salary of Robert Davis?
As the Senior Vice President and Chief Scientific Officer of Intra-Cellular Therapies Inc, the total compensation of Robert Davis at Intra-Cellular Therapies Inc is $2,128,540. There are 4 executives at Intra-Cellular Therapies Inc getting paid more, with Sharon Mates having the highest compensation of $4,724,560.
What's Robert Davis's mailing address?
Robert's mailing address filed with the SEC is C/O ACADIA PHARMACEUTICALS INC., 3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO, CA, 92121.
Insiders trading at Intra-Cellular Therapies Inc
Over the last 11 years, insiders at Intra-Cellular Therapies Inc have traded over $77,703,646 worth of Intra-Cellular Therapies Inc stock and bought 3,068,522 units worth $52,322,638 . The most active insiders traders include Rory B Riggs, Joel S Marcus und Christopher D Alafi. On average, Intra-Cellular Therapies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,787,280. The most recent stock trade was executed by Sharon Mates on 29 August 2024, trading 70,000 units of ITCI stock currently worth $891,100.
What does Intra-Cellular Therapies Inc do?
intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.
What does Intra-Cellular Therapies Inc's logo look like?
Complete history of Mr. Davis stock trades at Acadia Pharmaceuticals Inc und Intra-Cellular Therapies Inc
Intra-Cellular Therapies Inc executives and stock owners
Intra-Cellular Therapies Inc executives and other stock owners filed with the SEC include:
-
Sharon Mates,
Chairman of the Board, President, Chief Executive Officer -
Mark Neumann,
Executive Vice President, Chief Commercial Officer -
Michael Halstead,
Executive Vice President, General Counsel and Secretary -
Lawrence Hineline,
Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary -
Robert Davis,
Senior Vice President and Chief Scientific Officer -
Kimberly Vanover,
Senior Vice President, Early Stage Clinical Development and Translational Medicines -
Dr. Sharon Mates,
Co-Founder, Chairman, CEO & Pres -
Mark Neumann,
EVP & Chief Commercial Officer -
Michael I. Halstead J.D.,
Exec. VP, Gen. Counsel & Sec. -
Dr. Suresh K. Durgam M.D.,
Sr. VP & Chief Medical Officer -
Lawrence J. Hineline CPA, CPA,
Sr. VP of Fin., CFO, Treasurer & Assistant Sec. -
Robert Van Nostrand,
Lead Independent Director -
Joel Marcus,
Independent Director -
Christopher Alafi,
Independent Director -
Rory Riggs,
Independent Director -
Richard Lerner,
Independent Director -
Michael Olchaskey,
Senior Vice President, Head of Regulatory Affairs -
Suresh Durgam,
Chief Medical Officer -
John Bardi,
Senior Vice President - Market Access, Policy and Government Affairs -
Karen Patruno Sheehy Esq.,
Sr. VP & Chief Compliance Officer -
Juan Fernando Sanchez,
VP of Corp. Communications & Investor Relations -
Dr. Robert E. Davis Ph.D.,
Sr. VP & Chief Scientific Officer -
Moshe Alafi,
10% owner -
Capital Co Llc Alafi,
10% owner -
Juan F. Sanchez,
VP, Corp. Communications & IR -
Allen A. Fienberg,
VP of Business Development -
Lawrence P. Wennogle,
Vice President, Drug Discovery -
Michael Rawlins,
Director -
Eduardo Rene Salas,
-
Sanjeev Narula,
Executive Vice President & CFO